Story
Spruce Biosciences Stock Gains on Analyst Confidence, Positive FDA Update

Spruce Biosciences (NASDAQ:SPRB) shares rose more than 4% in pre-market trading after H.C. Wainwright reiterated its Buy rating on the stock, citing positive regulatory progress for the company's lead drug candidate.
Analyst Cites Positive FDA Feedback
H.C. Wainwright reaffirmed its Buy rating and $150 price target for Spruce Biosciences, according to a report from Investing.com. The firm's confidence is rooted in the company's completion of two constructive pre-Biologics License Application (BLA) meetings with the U.S. Food and Drug Administration (FDA).
The meetings concerned tralesinidase alfa (TA-ERT), an enzyme replacement therapy being developed for Sanfilippo Syndrome Type B. According to the source, the FDA signaled that Spruce's analytical strategies for the drug were "reasonable," a meaningful regulatory endorsement ahead of a planned BLA submission in the fourth quarter of 2026.
Broader Context and Market Support
The analyst note adds to a generally bullish sentiment for the company. The consensus rating among analysts covering Spruce is a Strong Buy, with price targets reportedly spanning from $104 to $230.
AdThis reaffirmation follows a $5.5 million strategic investment announced earlier in the month from the Cure Sanfilippo Foundation and the National MPS Society. The stock's move was also supported by a broader risk-on market tone, with the Nasdaq Composite and S&P 500 both trading higher, which tends to benefit small-cap biotechnology firms.
What This Means for Investors
Shares of Spruce Biosciences are known for high volatility, with a 52-week trading range of $7 to $240. This makes the stock particularly sensitive to news related to its clinical and regulatory milestones.
For investors, the combination of positive FDA feedback and renewed analyst confidence reinforces the timeline for the Q4 2026 BLA filing. This submission is widely seen as a potentially transformative catalyst for the company.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.